Lundbeck

Longboard Pharmaceuticals, Inc., established in 2020 and headquartered in San Diego, California, is engaged in developing optimized medicines targeting neurological diseases. The company focuses on improving pharmacology and pharmacokinetics to create novel treatments for rare conditions. Its pipeline includes LP352, a next-generation 5-HT2C agonist being evaluated for developmental and epileptic encephalopathies; LP143, a centrally acting CB2 receptor full agonist explored for potential treatment of neurological disorders like ALS and PD; and LP659, a highly selective S1P receptor modulator targeting multiple CNS neuroinflammatory disorders. Longboard operates as a subsidiary of Arena Pharmaceuticals, Inc., aiming to deliver these medicines to patients in need.

Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington, focused on discovering, developing, and commercializing therapeutic antibodies. The company aims to transform treatment paradigms for patients with migraine and other conditions, utilizing proprietary technologies to enhance the efficacy and durability of therapeutic responses. Its lead product candidate, eptinezumab, is a monoclonal antibody designed to prevent migraines, currently in late-stage clinical development. Additionally, Alder is developing ALD1910, a preclinical monoclonal antibody for migraine prevention, and Clazakizumab, which targets interleukin-6 and has completed two Phase 2b clinical trials. Alder also collaborates with CSL Limited to develop Clazakizumab for preventing solid organ transplant rejection. The company operates primarily in the United States, Australia, and Ireland, where it seeks to address unmet medical needs in various therapeutic areas, including cancer, autoimmune diseases, and inflammatory disorders. Founded in 2002, Alder BioPharmaceuticals operates as a subsidiary of H. Lundbeck A/S.

Abide Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing drugs that target serine hydrolases, a class of enzymes linked to various diseases with significant unmet medical needs. Founded in 2011, the company operates from its headquarters in San Diego, California, with an additional office in Princeton, New Jersey. Abide Therapeutics employs a specialized platform that enables the efficient identification, development, and validation of small-molecule inhibitors specifically designed to interact with serine hydrolases. This innovative approach allows for a deeper understanding of the roles these enzymes play in human disease and facilitates the discovery of selective inhibitors from a customized chemical library. As of 2019, Abide Therapeutics operates as a subsidiary of H. Lundbeck A/S.

Prexton Therapeutics SA is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It specializes in the development of innovative drugs for Parkinson's disease and other brain disorders. The company focuses on targeting metabotropic glutamate receptors, specifically mGluR4 and mGluR3, utilizing a novel scientific approach that integrates molecular, behavioral, and chemical technologies. Prexton Therapeutics aims to improve the quality of life for patients by offering alternatives to traditional dopaminergic treatments through its unique mGluR4 PAM series. This approach allows for quicker initiation of treatment, potentially leading to better medical outcomes for individuals suffering from these conditions.

BenevolentAI is a clinical-stage company specializing in AI-enabled drug discovery and development. By leveraging its advanced AI platform alongside scientific expertise and laboratory capabilities, the company aims to create novel drug candidates that demonstrate a higher likelihood of clinical success compared to traditional approaches. The Benevolent Platform supports a robust pipeline that includes over 20 drug programs, encompassing all stages from target discovery to clinical studies. Additionally, BenevolentAI collaborates with major pharmaceutical companies and leading research and charitable institutions to enhance its research efforts. The company is headquartered in London, with research facilities in Cambridge and an office in New York.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company based in Charlotte, North Carolina, specializing in the acquisition, development, and commercialization of treatments for various human diseases. The company is focused on developing a therapeutic agent for symptomatic neurogenic orthostatic hypotension and related conditions. Additionally, Chelsea Therapeutics is engaged in developing prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. The company's research efforts center on two main projects: droxidopa for symptomatic neurogenic orthostatic hypotension and a portfolio of non-metabolized antifolate compounds aimed at treating rheumatoid arthritis.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Proximagen is a publicly traded neuroscience research company specializing in drug development for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease. The company offers therapeutic drug development services, leveraging its expertise in medicinal chemistry, biology, and pharmacokinetics to create novel therapeutics targeting central nervous system diseases and inflammation.

Laboratoire Elaiapharm S.A., a pharmaceutical contract manufacturing organization, provides pharmaceutical development, manufacturing, and commercial and clinical packaging services. Its development services include feasibility studies, pre-formulation and formulation, process development and validation, galenic development, process optimization, reformulation and life cycle management, development and validation of analytical methods, ICH stabilities, and regulatory support and documentation. The company also engages in manufacturing solid dose, liquid, sterile, and non-sterile products, such as tablets, powders, hard capsules, vials, ampoules, bottles, drops, and active pharmaceutical ingredients. In addition, it offers primary and secondary packaging, clinical packaging, late stage customization, labeling, artworks management, and logistics and distribution services; and dossiers development and licensing services.

Ovation Pharmaceuticals, founded in 2000 and acquired by Lundbeck, Inc. in 2009, operates as a subsidiary focused on developing, manufacturing, and distributing prescription pharmaceuticals. The company primarily serves underserved patient groups with medically necessary products, particularly in the areas of central nervous system disorders, hematology, and oncology. Ovation Pharmaceuticals is involved in late-stage clinical development programs and offers a range of products, including various injections and tablets for conditions such as epilepsy and other neurological disorders. The company also specializes in acquiring under-marketed pharmaceuticals, leveraging its sales and marketing expertise to target concentrated physician specialty markets. Its products are marketed across multiple countries, including the United States, Canada, and several nations in Europe and Latin America.

Saegis Pharmaceuticals, established in 1999 and headquartered in Half Moon Bay, California, specializes in the development of medicines targeting cognitive dysfunction related to various central nervous system diseases. Its pipeline focuses on conditions such as Alzheimer's disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. The company aims to improve memory loss and cognition deficits stemming from aging, psychiatric disorders, and brain trauma through its CNS therapeutics.

Synaptic Pharmaceutical Corporation develops human receptor-targeted drug design technology. The Company offers technology which is used to discover and clone the genes that code for human receptor subtypes that may be associated with specific disorders.